PETCT Imaging Using 11C18F-METFET for Diagnosing Amino Acid Transporter System Disorders Including Primary Hyperparathyroidism and Glioma

What this Trial Is About

Researchers are evaluating the potential usefulness of 11C18F-METFET positron emission tomographycomputed tomography PETCT imaging for diagnosing primary and metastatic lesions in patients with various amino acid transporter system AATS-related diseases, including primary hyperparathyroidism and glioma. The study aims to measure how well this imaging method detects these lesions by analyzing uptake values and diagnostic accuracy. Each participant receives a single intravenous injection of the 11C18F-METFET tracer, followed by PETCT imaging within a specified time frame. This observational study involves patients undergoing the scan either for initial assessment or to detect recurrence of disease. The imaging uptake in lesions will be quantified using the maximum standardized uptake value SUVmax. Participants will be evaluated with PETCT scans, and the researchers will assess diagnostic measures such as sensitivity, specificity, positive predictive value, negative predictive value, and overall accuracy. The primary outcome is the standardized uptake value measured within 30 days, along with diagnostic efficacy. The total study period extends up to the end date in 2033, with assessments occurring shortly after imaging.

Amino Acid Transporter System PET/CT Imaging in AATS-Related Diseases